Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01588015 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01588015 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 36 participants.
The verdict
NCT01588015, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This randomized phase I trial studies the side effects of vaccine therapy in preventing cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor stem cell transplant. Vaccines made from a tetanus-CMV peptide or antigen may help the body build an effective immune response and prevent or delay the recurrence of CMV infection in patients undergoing donor stem cell transplant for hematological malignancies.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL tetanus-CMV fusion peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-10-29 |
| Est. Completion | 2024-02-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01588015
The ClinicalTrials.gov registry entry for NCT01588015 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT01588015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01588015 about?
NCT01588015 is a clinical study titled "Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant". This randomized phase I trial studies the side effects of vaccine therapy in preventing cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor stem cell transplant. Vaccines made from a tetanus-CMV peptide or antigen may help the body build an effective immune r...
What is the current status of trial NCT01588015?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2012-10-29. Estimated completion is 2024-02-02.
What interventions are being tested in trial NCT01588015?
The interventions under investigation include: laboratory biomarker analysis (OTHER), tetanus-CMV fusion peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01588015?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.